ReNeuron Group plc Block Listing Review and Total Voting Rights (5776Q)

TIDMRENE

RNS Number : 5776Q

ReNeuron Group plc

01 March 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                               ReNeuron Group plc 
 Name of Scheme:                     ReNeuron Share Option Schemes 
                                    ------------------------------ 
 Period of Return:                   From 1 September 2020 to 
                                      28 February 2021 
                                    ------------------------------ 
 Balance of unallotted securities    674,687 Ordinary Shares (of 
  under scheme(s) from previous       1p each) 
  return: 
                                    ------------------------------ 
 Plus: The amount by which           N/A 
  the block scheme(s) has been 
  increased since the date 
  of the last Review (if any 
  increase has been applied 
  for): 
                                    ------------------------------ 
 Less: Number of securities 
  issued/allotted under scheme(s) 
  during period                      11,000 
                                    ------------------------------ 
 Equals: Balance under scheme(s)     663,687 Ordinary Shares 
  not yet issued/allotted at 
  end of period: 
                                    ------------------------------ 
 Number and class of securities      20,000 ordinary shares on 
  originally admitted and the         13 May 2010 
  date of admission: 
                                    ------------------------------ 
 

Total Voting Rights

At 28 February 2021, the Company had 56,855,705 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

 
 ReNeuron                                                     www.reneuron.com/investors 
 Olav Hellebø, Chief Executive                                      Via Walbrook PR 
  Officer 
 Michael Hunt, Chief Financial Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                      [phone] 
 
 Allenby Capital Limited (Joint Broker)                              [phone] 
 James Reeve/George Payne (Corporate 
  Finance) 
 Tim Sohal (Sales & Corporate Broking) 
 
 Walbrook PR (Media & Investor            [phone] or [e-mail] 
  Relations) 
                                                       [phone] / +44 (0)7407 
 Paul McManus, Alice Woodings                                                    804 654 
 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDKABQABKDNBB

(END) Dow Jones Newswires

March 01, 2021 02:00 ET (07:00 GMT)